Shares of BTG plc (LON:BTG) have received an average recommendation of “Buy” from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is GBX 780.43 ($10.78).
A number of research firms recently issued reports on BTG. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of BTG in a research note on Monday, January 15th. Peel Hunt reaffirmed a “hold” rating and set a GBX 700 ($9.67) price target on shares of BTG in a research note on Thursday, February 1st. Finally, Numis Securities reaffirmed a “buy” rating and set a GBX 900 ($12.43) price target on shares of BTG in a research note on Wednesday, January 24th.
BTG stock traded up GBX 2 ($0.03) during trading on Wednesday, reaching GBX 659 ($9.10). 536,013 shares of the company were exchanged, compared to its average volume of 582,586. The stock has a market capitalization of $2,640.00 and a P/E ratio of 3,468.42. BTG has a 52 week low of GBX 559.82 ($7.73) and a 52 week high of GBX 784 ($10.83).
TRADEMARK VIOLATION WARNING: “BTG plc (BTG) Receives GBX 780.43 Average Target Price from Analysts” was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3297299/btg-plc-btg-receives-gbx-780-43-average-target-price-from-analysts.html.
BTG Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.